PROK - NASDAQ

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%

HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$581.72M

EPS-0.5200

P/E Ratio-3.33

Earnings Date08/06/2026

prok

Stock Based Compensation

Last Annual Value

25.34M

3-Year CAGR

-30%

5-Year CAGR

103%

10-Year CAGR

196%

Adjust for Inflation

ProKidney Corp. Competitors Analysis of Stock Based Compensation

PROK · NASDAQ

Company	Stock Based Compensation	CAGR 3Y	CAGR 5Y	CAGR 10Y
ProKidney Corp. NASDAQ:PROK	25.34M	-6.3%	105.0%	N/A
Septerna, Inc. NASDAQ:SEPN	8.48M	73.6%	N/A	N/A
Kura Oncology, Inc. NASDAQ:KURA	37.11M	9.7%	9.5%	33.3%
Prime Medicine, Inc. NASDAQ:PRME	29.27M	28.1%	75.7%	N/A
Savara Inc. NASDAQ:SVRA	14.42M	51.1%	34.6%	52.7%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	15.01M	99.2%	N/A	N/A
AnaptysBio, Inc. NASDAQ:ANAB	36.07M	2.8%	18.6%	41.0%
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	0.00	N/A	N/A	N/A
Precigen, Inc. NASDAQ:PGEN	10.87M	3.2%	-4.8%	-14.7%
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	28.72M	-13.9%	11.3%	N/A
Xencor, Inc. NASDAQ:XNCR	43.23M	N/A	3.2%	18.6%

ProKidney Corp. Fair Value Envelope

PROK · NASDAQ

Our analysis suggests that PROK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.73, this represents a potential HIDDEN relative to our calculated worth for ProKidney Corp..

HIDDEN

Intrinsic Value

Current Price: $1.73

Related Guides

Blog Categories

Continue your PROK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.